More reads
- It’s just in mice! This scientist is calling out hype in science reporting. (STAT)
- Contract drug manufacturer Catalent to buy Paragon Bioservices in $1.2 billion deal. (Wall Street Journal)
- Hatteras launches new fund with $94 million for life science investments. (Xconomy)
- The health policy experts shaping Nancy Pelosi’s approach to drug pricing. (STAT Plus)
No hay comentarios:
Publicar un comentario